Showing results (221-230 of 319) with videos related to
Sort By:
Pageof 32
Leukemia|January 8, 2025
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CMLReinhard Brunmeir, Li Ying, Junli Yan, et al.Oncogene|February 22, 2022
p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)Phaik Ju Teoh, Omer An, Tae-Hoon Chung, et al.Molecular Cancer Therapeutics|May 6, 2015
MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell CarcinomaLi Ren Kong, Kian Ngiap Chua, Wen Jing Sim, et al.Pharmacogenetics and Genomics|October 8, 2009
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancerSoo-Chin Lee, Xin Xu, Wee-Joo Chng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.Cellular Microbiology|November 1, 2017
Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidaseJessamine G Goh, Sharada Ravikumar, Mar Soe Win, et al.Clinical Hematology International|May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working groupWenming Chen, Zhen Cai, Chor Sang Chim, et al.Haematologica|December 21, 2023
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myelomaPhyllis S Y Chong, Jing Yuan Chooi, Sze Lynn Julia Lim, et al.Clinical Hematology International|August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working GroupWenming Chen, Zhen Cai, Chor Sang Chim, et al.Blood Cancer Journal|June 17, 2025
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, et al.Pageof 32